In 2004, Mark Lundstrom must decide on the method of financing and strategic approach to BioScale, a biotechnology company he founded. BioScale developed a microchip-based bioanalytical platform which can be used to detect very low concentrations of cells, viruses, proteins or small molecules. The company has several multi-billion dollar market in their sights. Up to this point, Lundstrom used a combination of individual and angel capital funding and government subsidies to meet the company's capital needs. Now he must decide whether to continue on its current "go slow to go fast strategy" or, conversely, to raise a significant round of capital or find a strategic partner. Lundstrom also explored career as an entrepreneur in the scientific and business. "Hide
by H. Kent Bowen, Bradley R. Staats Source: Harvard Business School 24 pages. Publication Date: June 21, 2006. Prod. #: 606100-PDF-ENG
Related Case Solutions & Analyses:
Baosteel Group: Governance with Chinese Characteristics
TOTO: The Bottom Line
Friendster (B)
ORIX KK: Incentives in Japan
Note on Drawing Implications from Themes
Wells Fargo and Norwest: Merger of Equals (A)
Market Research
CASE ANALYSIS: SCHON KLINIK EATING DISORDER
COLA- WARS CONTINUE
Decision for taking Quattroporte Inc. Global
